Dazukibart
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Dermatomyositis
Conditions
Dermatomyositis, Polymyositis
Trial Timeline
Jan 22, 2025 → Nov 25, 2027
NCT ID
NCT06698796About Dazukibart
Dazukibart is a phase 3 stage product being developed by Pfizer for Dermatomyositis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06698796. Target conditions include Dermatomyositis, Polymyositis.
What happened to similar drugs?
0 of 2 similar drugs in Dermatomyositis were approved
Approved (0) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06698796 | Phase 3 | Recruiting |
Competing Products
14 competing products in Dermatomyositis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| tacrolimus | Astellas Pharma | Pre-clinical | 26 |
| M5049 high dose + Placebo | Merck | Phase 2 | 27 |
| BAF312 + Placebo | Novartis | Phase 2 | 27 |
| MEDI7734 + Placebo | Amgen | Phase 1 | 29 |
| Etanercept + Placebo | Amgen | Phase 1 | 29 |
| Anti-Beta Interferon (PF-06823859) | Pfizer | Phase 2 | 35 |
| PF-06823859 low + Placebo Arm + PF-06823859 high | Pfizer | Phase 2 | 35 |
| Tofacitinib | Pfizer | Phase 1 | 29 |
| Emapalumab | Swedish Orphan Biovitrum | Phase 2 | 42 |
| human immunoglobulin G + Placebo | CSL | Phase 3 | 32 |
| Empasiprubart IV | Argenx | Phase 2 | 36 |
| GLPG3667 + Placebo | Galapagos | Phase 2 | 33 |
| Lenabasum 20 mg + Lenabasum 5 mg + Placebo | Corbus Pharmaceuticals | Phase 3 | 30 |
| JBT-101 + Placebo | Corbus Pharmaceuticals | Phase 2 | 17 |